Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

- PMLiVE

AZ’s Lynparza closes in on first line ovarian cancer use

Aims for first-line indication in the ovarian cancer setting

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

Medical information in precision medicine

Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.

Blue Latitude Health

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

ACT immunotherapy cures terminal breast cancer patient

The new approach focuses on mutations rather than cancer type

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Research Partnership

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

AbbVie trial backs chemo-free Imbruvica combo regimen

Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients

Eli Lilly HQ

Lilly adds AurKa Pharma to oncology buying spree

Lilly is buying back its former drug after just two years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links